Introduction
Malignant tumors are biologically complex and exhibit substantial spatial variation in gene expression, biochemistry, histopathology and macroscopic structure. Cancerous cells not only undergo clonal evolution from a single progenitor cell into more aggressive and therapy resistant cells, but also exhibit branched evolution, whereby each tumor develops and preserves multiple distinct sub-clonal populations (1) . This genetic heterogeneity (1, 2), combined with spatial variation in environmental stressors, leads to regional differences in stromal architecture (3) oxygen consumption (4, 5), glucose metabolism (4) and growth factor expression (6). Consequently, tumor subregions develop, each with spatially distinct patterns of blood flow (7, 8), vessel permeability (9), cell proliferation (10), cell death (11) and other features.
Spatial heterogeneity is found between different tumors in individual patients
(intertumor heterogeneity) and within each lesion (intratumor heterogeneity). Intratumor heterogeneity is near ubiquitous in malignant tumors, but the extent varies between preclinical cancer models and between patients (12). Allowing for these differences, some common themes emerge. Firstly, intratumor heterogeneity is dynamic. For example, variations in tumor pO 2 fluctuate over minutes to hours (5, 6). Secondly, intratumor heterogeneity tends to increase as tumors grow (7, 13). Thirdly, established spatial heterogeneity frequently indicates poor clinical prognosis (14) , in part due to resistant Imaging depicts spatial heterogeneity in tumors. However, while imaging is central to diagnosis, staging, response assessment and recurrence detection in routine oncological practice, most clinical radiology and research studies only measure tumor size or average parameter values, such as median blood flow (18) . In doing so, spatially rich information is discarded. There has been considerable effort to use more sophisticated analyses to either quantify overall tumor spatial complexity or identify the tumor sub-regions that may drive disease transformation, progression and drug resistance (11, 19) .
In this review we highlight the strengths and weaknesses of methods that measure intratumor spatial heterogeneity ( Fig. 1 and Table 1 ). We evaluate evidence that heterogeneity analyses provide any clinical benefit over simple 'average value' measurements. We discuss how imaging, genomic and pathology biomarkers of intratumor heterogeneity relate to one another. Finally, we identify the hurdles to translating image biomarkers of spatial heterogeneity into clinical practice.
Qualitative Assessment of Heterogeneity
Radiologists use qualitative descriptors to describe adverse spatial features and functional heterogeneity on clinical scans. For example, when assessing pulmonary nodules on CT (20) and breast lumps on x-ray mammography (21), spiculation implies greater risk of malignancy compared with well circumscribed lesions. Indeed, spiculate morphology is part of the BI-RADS lexicon that classifies breast lesions as 'radiologically malignant' (22).
Identifying a tumor 'hot spot' is also commonplace in cancer radiology. The established proxy for identifying abnormal glucose metabolism, based on identifying the one or more voxels with greatest abnormality. Measuring SUV max is simple, reproducible (23, 24) and can be performed on clinical workstations. The presence of abnormal glycolysis in part of a tumor using SUV max is used widely to stage and monitor response in several malignant tumors (25). In glioma, regional high values of tracer uptake ( 18 F-FDG and 11 C-methionine) have been used to grade tumors using targeted biopsy (26).
Perfusion CT and MRI methods employ 'hot spot' analysis to identify tumor regions with the most abnormal vascular features. Specialist neuro-oncology centres use dynamic contrast-enhanced MRI (DCE-MRI) or dynamic susceptibility contrast MRI (DSC-MRI) in patients with high grade glioma (HGG) to map relative cerebral blood volume (rCBV) (27) based on the rationale that 'more vascular' regions correspond to highest malignant grade and that this improves prognostic assessment in patients. It is important to note that hot spot analyses are subjective, only identify regions that are maximum (or minimum when gray scale is inverted) and that observer evaluation of heterogeneity is highly influenced by display ranges and color schemes (28) unless objective algorithms are employed.
Voxels: Considerations for Quantifying Heterogeneity
Imaging modalities measure biophysical signals in tissues and spatially encode these signals to create clinical images or parameter maps composed of three dimensional picture elements called voxels. Heterogeneity analyses combine data from many voxels. Several issues arise when interpreting these data.
Firstly, some voxels suffer partial volume averaging (typically at interface with non-tumor tissue). Secondly, there is inevitable compromise between having sufficient
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numbers of voxels to perform the analysis versus sufficiently large voxels to overcome noise and keep imaging times practical (29) . Most analysis methods require hundreds to thousands of voxels for robust application. Thirdly, many studies of tumor spatial heterogeneity have used standard clinical data from protocols dictated by clinical rather than research needs. In some cases sections of tumor were omitted when noncontiguous tumor sampling was used (30) which may confound 3D spatial analyses 
Measuring Degree of Heterogeneity: Quantifying Parameter Distributions
Voxel values can be plotted as histograms, from which many simple descriptors can be extracted as potential biomarkers. These include simple descriptors of image heterogeneity such as standard deviation, interquartile range, n th centile(s), skew and kurtosis ( Supplementary Fig. S1 ), as well as mean and median values (34) . In these approaches the inherent spatial relationship between voxels is discarded and data are treated as a list of continuous variables.
Histogram analysis
Histograms can be generated using widely available software and have proved popular 
Fractal analysis and Minkowski functionals
Fractal dimensions estimate the complexity of geometrical patterns resulting from abstract recursive procedures (50). The simplest fractal dimension is the box-counting dimension (d 0 ), computed by imposing regular grids of a range of scales on a binary object in question and then counting the number of grid elements (boxes) that are occupied by the object at each scale ( Supplementary Fig. S3 ). The box counting dimension is the slope of the line of best fit when plotting the number of occupied boxes against the reciprocal of the scale on log-log axes (51 
Evidence for clinical benefit
Texture analyses have been used extensively in x-ray mammography (52) . Early applications included discrimination of glandular and fatty regions in mammograms (53) and distinguishing benign and malignant lesions (31 
Identifying Tumor Subregions
Tumor images contain hundreds-thousands of voxels. Grouping 'similar' voxels together underlying assumptions and methodology. Some use prior knowledge whereas others rely solely on information contained within the image(s) (Fig. 3) . 
Parcellation using a priori assumptions
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Evidence for clinical benefit
Multiple studies of HGG patients have shown lower baseline lesion enhancing tumor volume (ETV) had beneficial OS (p=0.0026) (67) or PFS (p=0.0309) (68) and that early reduction in ETV after bevacizumab related to OS (p=0.0008) (69) (78) and to anti-VEGF antibody (79) (Fig. 4) .
Multispectral analyses of baseline data that identify tumor sub-regions with distinct biology, responsible for driving tumor response, resistance and progression are highly attractive, although performed rarely. Algorithms to perform this are commercially available (80) .
In distinction, it is very difficult to track changes in individual voxels as tumors change shape and size. Some progress has been made in studies of HGG using a method termed 'response parametric mapping' where rCBV and ADC maps have been categorized as showing no change or increasing/decreasing by greater than 20% following therapy. The proportion of tumor with reduced rCBV related to OS (p=0.019), where mean rCBV did not (81) . However, it is extremely difficult to extend this approach to accommodate changes in tumor size, orientation and deformation, which make translation of these methods from specialist laboratories to healthcare systems extremely challenging.
Integrating Imaging, Genomics, and Histopathology
values, have been shown to correctly categorize oligodendrogliomas by their 1p/19q loss status (85).
These data highlight the need for larger prospective studies to elucidate how and when integration of imaging, genomic and pathology data may be useful. These studies must evaluate large complex data across a range of biological different scales (15, 32) . 
Future Directions and Conclusions
Diverse philosophical and mathematical approaches can quantify intratumor heterogeneity. Most techniques can be applied across all imaging modalities, while some require datasets with multiple signals. Each method has strengths and limitations (Table 2) . Advances in hardware such as simultaneous PET-MRI and whole body imaging with MRI diffusion will further stimulate imaging research into analysis of both intratumor heterogeneity and in differences between multiple lesions within individuals. 
